Search results for "ATHEROSCLEROSIS"

showing 10 items of 499 documents

Ezetimibe, cardiovascular risk and atherogenic dyslipidaemia.

2010

Ezetimibe is a selective cholesterol absorption inhibitor with an excellent side-effect profile, able to reduce low-density lipoprotein (LDL) cholesterol by 15-25% from baseline in monotherapy and on top of statins and fibrates. Yet, it seems that ezetimibe produces quantitative rather than qualitative changes in LDL, with small net effects on atherogenic dyslipidaemia. This is supported by findings from the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) study on atherosclerosis progression, where the addition of ezetimibe to simvastatin in patients with heterozygous familial hypercholesterolaemia did not affect the mean change in carotid int…

cardiovascular riskAortic valvemedicine.medical_specialtydyslipidaemiamedicine.drug_classezetimibe cardiovascular risk atherosclerosis dyslipidaemiachemistry.chemical_compoundEzetimibeInternal medicineClinical endpointMedicineCholesterol absorption inhibitorcardiovascular diseasesReview Paperbusiness.industryCholesterolnutritional and metabolic diseasesGeneral Medicinemedicine.diseaseStenosismedicine.anatomical_structureEndocrinologychemistrySimvastatinCardiologylipids (amino acids peptides and proteins)atherosclerosisbusinessezetimibeLipoproteinmedicine.drug
researchProduct

Carotid Artery Disease in the Era of Biomarkers: A Pilot Study

2023

The intima-media thickness (IMT) and its irregularities or ulcerations in the common carotid artery (CCA) are useful tools as sentinel biomarkers for the integrity of the cardiovascular system. Total homocysteine and lipoprotein levels are the most commonly used elements in cardiovascular risk stratification. Duplex ultrasound (DUS), associated with serum biomarkers, can be used simply to assess the degree of atherosclerotic disease and cardiovascular risk. This study highlights the role of different kinds of biomarkers, showing their usefulness and potentiality in multi-district atherosclerotic patients, especially for early diagnosis and therapy effectiveness monitoring. A retrospective a…

cardiovascular riskClinical Biochemistrybiomarkerscarotid artery diseaseAtherosclerosisintima-media thickness
researchProduct

European Panel on Low Density Lipoprotein (LDL) Subclasses: A Statement on the Pathophysiology, Atherogenicity and Clinical Significance of LDL Subcl…

2011

Item does not contain fulltext Aim of the present Consensus Statement is to provide a comprehensive and up to-date document on the pathophysiology, atherogenicity and clinical significance of low density liproproteins (LDL) subclasses. We sub-divided our statement in 2 sections. section I discusses the pathophysiology, atherogenicity and measurement issues, while section II is focused on the effects of drug and lifestyle modifications. Suggestions for future research in the field are highlighted at the end of section II. Each section includes Conclusions.

cardiovascular riskischemic-heart-diseaseHealth aging / healthy living [IGMD 5]coronary-artery-diseaseapolipoprotein-b metabolismcholesteryl ester transferAtherosclerosisstatementfamilial combined hyperlipidemialdlLipoproteins LDLvery-low-densitynuclear-magnetic-resonancec-reactive proteinRisk FactorsAnimalsHumansGenetic Predisposition to DiseaseLDL subclasses atherosclerosis cardiovascular risk statementsubclassesatherosclerosistype-2 diabetes-mellitusintima-media thickness
researchProduct

Small, dense LDL: An update

2017

Purpose of review In this review, we summarize the latest findings on small, dense LDL (sdLDL) atherogenic particles, including their associations with other biomarkers. Recent findings Increased sdLDL levels have been reported not only in different metabolic disorders such as diabetes, obesity and metabolic syndrome, but also in patients with rheumatoid and psoriatic arthritis as well as hypothyroidism. A wide range of lipid-lowering, as well as other drug classes, including novel antidiabetic agents and nutraceuticals, exert favourable effects on these atherogenic particles. The 'gold standard' methodology for the assessment of sdLDL has not been established yet. However, the association …

cardiovascular riskmedicine.medical_specialtySmall dense ldl10265 Clinic for Endocrinology and Diabetology030209 endocrinology & metabolism610 Medicine & health030204 cardiovascular system & hematology2705 Cardiology and Cardiovascular Medicine03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRisk FactorsInternal medicineDiabetes mellitusCardiovascular DiseaseMedicineHumansParticle SizeMetabolic Syndromebusiness.industryCholesterollipid-lowering therapieBiomarkerCholesterol LDLmedicine.diseaseAtherosclerosisObesityEndocrinologychemistrysmall dense LDLs: AtherosclerosiCardiovascular DiseasesCardiology and Cardiovascular MedicinebusinessBiomarkers
researchProduct

Treatment options for managing atherogenic dyslipidemia and fatty liver disease

2014

Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in Western countries with up to 30% of the population affected. Since NAFLD is associated with an increased risk of cardiovascular (CV) disease, these patients should be stratified for CV risk factors, including atherogenic dyslipidemia, and managed accordingly. Lifestyle modifications represent an effective treatment for NAFLD, since most patients are overweight or obese. Also, promising, but not conclusive, results are available for current pharmacologic treatment. Drugs potentially effective against NAFLD include insulin sensitisers as well as fibrates and omega-3 polyunsaturated fatty acids, whil…

cardiovascular riskmedicine.medical_specialtymedicine.medical_treatmentPopulationcardiovascular risk dyslipidemia non-alcoholic fatty liver disease therapyDiseaseOverweightdyslipidemia fatty liver disease treatmentChronic liver diseaseBioinformaticsInternal medicineFatty Acids Omega-3medicineHumansPharmacology (medical)educationDyslipidemiaschemistry.chemical_classificationPharmacologyeducation.field_of_studytherapybusiness.industryInsulinMedicine (all)Fatty liverdyslipidemiaFibric Acidsnutritional and metabolic diseasesnon-alcoholic fatty liver diseaseGeneral Medicinemedicine.diseaseAtherosclerosisEndocrinologychemistrymedicine.symptomHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessDyslipidemiaPolyunsaturated fatty acid
researchProduct

Carotid intimal-media thickness and endothelial function in young patients with history of myocardial infarction

2009

AIM: The aim of the study was to evaluate the prevalence of carotid atherosclerosis and endothelial dysfunction in 45 young patients (38 mens and 7 females) with myocardial infarction (MI), age 29-45, mean age 42+/-3 years, to verify its possible role as a marker of coronary atherosclerosis. METHODS: Vascular echography was performed to verify the presence of carotid atherosclerosis and/or endothelial dysfunction in 45 young patients with MI and in 45 healthy control subjects well matched for age and sex. RESULTS: We observed a normal intima media thickness (IMT) only in 30% of patients with juvenile myocardial infarction (JMI) compared with 66% in the control group (P<0.0001) and 34% of pa…

carotid atherosclerosis; juvenile myocardial infarction; endothelial function; atherosclerosis.endothelial functionatherosclerosis.juvenile myocardial infarctionSettore MED/11 - Malattie Dell'Apparato Cardiovascolarecarotid atherosclerosi
researchProduct

ANP IMUUNOLOCALITATION IN INTERNAL CAROTID ARTERY WALL OF SUBJECTS WITH AN WITHOUT ATHEROSCLEROTIC LESIONS

2008

carotidatherosclerosisSettore BIO/16 - Anatomia Umana
researchProduct

Analysis of the metabolic switch induced by the spirulina peptide SP6 in high fat diet ApoE-/-mice model: A direct infusion FT-ICR-MS based approach

2021

Atherosclerosis, dyslipidemia and hypertension are comorbid diseases often found in combination. Among different pharmacological approaches the employment of natural multifunctional peptides is an attractive option as side therapy. Mass spectrometry-based metabolomics provide valuable information on metabolic changes and can be useful to elucidate peptide pharmacodynamics. In this this work we performed a preliminary investigation on the potential effect of a recently characterized Spirulina platensis peptide named SP6 (GIVAGDVTPI) on the modulation of metabolism in a high fat diet ApoE-/- mice atherosclerotic model. A direct infusion Fourier transform ion cyclotron resonance mass spectrome…

chemistry.chemical_classificationResolution (mass spectrometry)010405 organic chemistryChemistry010401 analytical chemistryClinical BiochemistryPharmaceutical SciencePeptideMetabolismPharmacologymedicine.diseaseMass spectrometry01 natural sciencesSphingolipidAtherosclerosis FT-ICR Metabolomics Peptide Spirulina0104 chemical sciencesAnalytical ChemistryAmino acidMetabolomicsDrug DiscoverymedicineSpectroscopyDyslipidemia
researchProduct

Zinc and inflammatory/immune response in aging

2007

Life-long antigenic burden determines a condition of chronic inflammation, with increased lymphocyte activation and proinflammatory cytokine production. A large number of studies have documented changes in zinc metabolism in experimental animal models of acute and chronic inflammation and in human chronic inflammatory conditions. In particular, modification of zinc plasma concentration, as well as intracellular disturbance of antioxidant intracellular pathways, has been found in aging and in some age-related diseases. Zinc deficiency is diffused in aged individuals in order to avoid meat and other high zinc content foods due to fear of cholesterol. Rather, they increase the consumption of r…

chemistry.chemical_elementInflammationZincBiologyModels BiologicalAntioxidantsGeneral Biochemistry Genetics and Molecular BiologyProinflammatory cytokinechemistry.chemical_compoundImmune systemHistory and Philosophy of SciencemedicineAnimalsHumansModels GeneticInterleukin-6Tumor Necrosis Factor-alphaGeneral NeuroscienceagingzincNF-kappa BNF-κBAtherosclerosismedicine.diseasemetallothioneinDiabetes Mellitus Type 2chemistryinflammationImmune SystemImmunologyZinc deficiencymedicine.symptomIntracellularHomeostasis
researchProduct

Design and rationale of a nationwide screening analysis from the LIPIDOGRAM2015 and LIPIDOGEN2015 studies.

2022

IntroductionCardiovascular disease (CVD) is a major cause of morbidity and mortality throughout the world. The LIPIDOGRAM2015 study was performed to estimate the prevalence of risk factors for atherosclerotic diseases as well as cardiovascular and related disorders in the primary care setting in Poland. The LIPIDOGEN2015 sub-study was designed to include a random cohort of patients in order to analyse parameters related to lipid metabolism, oxidative stress, inflammatory responses, autoimmune disorders, and gene variants that confer susceptibility to cardiometabolic and atherosclerotic diseases.Material and methodsThe recruitment was carried out by 438 primary care physicians in Poland. The…

dyslipidaemiabusiness.industryGeneral Medicinemedicine.diseaseBioinformaticsmedicine.disease_causeScreening analysiscardiovascular diseasesinflammationmedicineoxidative stressatherosclerosisbusinesscardiometabolic diseasesgenesDyslipidemiaOxidative stressArchives of medical science : AMS
researchProduct